Renal effects of immune checkpoint inhibitors

被引：74

作者：

Izzedine, Hassan ^{[1
]}

Mateus, Christine ^{[2
]}

Boutros, Celine ^{[2
]}

Robert, Caroline ^{[2
]}

Rouvier, Philippe ^{[3
]}

Amoura, Zahir ^{[4
]}

Mathian, Alexis

机构：

[1] Monceau Pk Int Clin Paris, Dept Nephrol, Paris, France

[2] Gustave Roussy Inst, Dept Oncol, Villejuif, France

[3] Hop La Pitie Salpetriere, Dept Pathol, Paris, France

[4] Hop La Pitie Salpetriere, Dept Internal Med 2, Paris, France

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2017年 / 32卷 / 06期

关键词：

checkpoint blockade; immunotherapy; ipilimumab; nivolumab; pembrolizumab; OVERCOMING IMMUNOLOGICAL-TOLERANCE; ACUTE INTERSTITIAL NEPHRITIS; MELANOMA TARGETING CTLA-4; ANTI-PD-1; ANTIBODY; PHASE-II; IPILIMUMAB; NIVOLUMAB; SAFETY; BLOCKADE; PEMBROLIZUMAB;

D O I：

10.1093/ndt/gfw382

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

Recent advances in immune checkpoint inhibitor (ICPI) development have led to major improvements in oncology patient outcomes. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are two essential immune checkpoint receptors. Ipilimumab and tremelimumab (anti-CTLA-4-blocking antibodies) and pembrolizumab and nivolumab (antibodies targeting PD-1 receptors) have already been approved by US Food and Drug Administration in several malignancies. Two different forms of ICPI-induced renal damage have been identified, including acute (granulomatous) tubulointerstitial nephritis and immune complex glomerulonephritis. The observed acute renal damage can be reversed upon ICPI drug discontinuation and renal function can recover back to normal following the introduction of systemic corticosteroid treatment. Any delay in treating this complication could result in definitive and irreversible renal injury.

引用

页码：936 / 942

页数：7

共 72 条

[61] Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab [J].

Topalian, Suzanne L. ;

Sznol, Mario ;

McDermott, David F. ;

Kluger, Harriet M. ;

Carvajal, Richard D. ;

Sharfman, William H. ;

Brahmer, Julie R. ;

Lawrence, Donald P. ;

Atkins, Michael B. ;

Powderly, John D. ;

Leming, Philip D. ;

Lipson, Evan J. ;

Puzanov, Igor ;

Smith, David C. ;

Taube, Janis M. ;

Wigginton, Jon M. ;

Kollia, Georgia D. ;

Gupta, Ashok ;

Pardoll, Drew M. ;

Sosman, Jeffrey A. ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) :1020-+

[62] Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer [J].

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Brahmer, Julie R. ;

Gettinger, Scott N. ;

Smith, David C. ;

McDermott, David F. ;

Powderly, John D. ;

Carvajal, Richard D. ;

Sosman, Jeffrey A. ;

Atkins, Michael B. ;

Leming, Philip D. ;

Spigel, David R. ;

Antonia, Scott J. ;

Horn, Leora ;

Drake, Charles G. ;

Pardoll, Drew M. ;

Chen, Lieping ;

Sharfman, William H. ;

Anders, Robert A. ;

Taube, Janis M. ;

McMiller, Tracee L. ;

Xu, Haiying ;

Korman, Alan J. ;

Jure-Kunkel, Maria ;

Agrawal, Shruti ;

McDonald, Daniel ;

Kollia, Georgia D. ;

Gupta, Ashok ;

Wigginton, Jon M. ;

Sznol, Mario .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2443-2454

[63] Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies [J].

Troxell, Megan L. ;

Higgins, John P. ;

Kambham, Neeraja .

ADVANCES IN ANATOMIC PATHOLOGY, 2016, 23 (05) :310-329

[64] Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab [J].

Vandiver, Jeremy W. ;

Singer, Zachary ;

Harshberger, Cara .

TARGETED ONCOLOGY, 2016, 11 (04) :553-556

[65] The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network [J].

Voskens, Caroline J. ;

Goldinger, Simone M. ;

Loquai, Carmen ;

Robert, Caroline ;

Kaehler, Katharina C. ;

Berking, Carola ;

Bergmann, Tanja ;

Bockmeyer, Clemens L. ;

Eigentler, Thomas ;

Fluck, Michael ;

Garbe, Claus ;

Gutzmer, Ralf ;

Grabbe, Stephan ;

Hauschild, Axel ;

Hein, Ruediger ;

Hundorfean, Gheorghe ;

Justich, Armin ;

Keller, Ullrich ;

Klein, Christina ;

Mateus, Christine ;

Mohr, Peter ;

Paetzold, Sylvie ;

Satzger, Imke ;

Schadendorf, Dirk ;

Schlaeppi, Marc ;

Schuler, Gerold ;

Schuler-Thurner, Beatrice ;

Trefzer, Uwe ;

Ulrich, Jens ;

Vaubel, Julia ;

von Moos, Roger ;

Weder, Patrik ;

Wilhelm, Tabea ;

Goeppner, Daniela ;

Dummer, Reinhard ;

Heinzerling, Lucie M. .

PLOS ONE, 2013, 8 (01)

[66] LYMPHOPROLIFERATIVE DISORDERS WITH EARLY LETHALITY IN MICE DEFICIENT IN CTLA-4 [J].

WATERHOUSE, P ;

PENNINGER, JM ;

TIMMS, E ;

WAKEHAM, A ;

SHAHINIAN, A ;

LEE, KP ;

THOMPSON, CB ;

GRIESSER, H ;

MAK, TW .

SCIENCE, 1995, 270 (5238) :985-988

[67] Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010) [J].

Weber, Jeffrey .

ONCOLOGIST, 2008, 13 :16-25

[68]

Weber JS, 2015, J CLIN ONCOL, V33

[69] Toxicities of Immunotherapy for the Practitioner [J].

Weber, Jeffrey S. ;

Yang, James C. ;

Atkins, Michael B. ;

Disis, Mary L. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2092-U154

[70] Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial [J].

Weber, Jeffrey S. ;

D'Angelo, Sandra P. ;

Minor, David ;

Hodi, F. Stephen ;

Gutzmer, Ralf ;

Neyns, Bart ;

Hoeller, Christoph ;

Khushalani, Nikhil I. ;

Miller, Wilson H., Jr. ;

Lao, Christopher D. ;

Linette, Gerald P. ;

Thomas, Luc ;

Lorigan, Paul ;

Grossmann, Kenneth F. ;

Hassel, Jessica C. ;

Maio, Michele ;

Sznol, Mario ;

Ascierto, Paolo A. ;

Mohr, Peter ;

Chmielowski, Bartosz ;

Bryce, Alan ;

Svane, Inge M. ;

Grob, Jean-Jacques ;

Krackhardt, Angela M. ;

Horak, Christine ;

Lambert, Alexandre ;

Yang, Arvin S. ;

Larkin, James .

LANCET ONCOLOGY, 2015, 16 (04) :375-384

← 1 2 3 4 5 6 7 8 →